Summary Box: Merck-Drug Pipeline
PIPELINE ANNOUNCED: Merck & Co., barely 100 days after buying Schering-Plough Corp., says it now has 43 drugs in mid- and late-stage testing, almost double what it did.
WHAT'S IN TESTING: Drugs that would be the first in a class, for preventing blood clots and for hepatitis C, are in final human testing. Other drugs and vaccines are in development for diabetes, insomnia, schizophrenia, cancer, heart disease, glaucoma and infectious diseases.
WHY IT'S IMPORTANT: Like its rivals, Merck increasingly is losing sales to generic drugs, so it needs new medicines to compensate.